A detailed history of Northern Trust Corp transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 379,375 shares of KALV stock, worth $3.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
379,375
Previous 332,695 14.03%
Holding current value
$3.15 Million
Previous $3.92 Million 12.09%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$9.46 - $15.39 $441,592 - $718,405
46,680 Added 14.03%
379,375 $4.39 Million
Q2 2024

Aug 14, 2024

BUY
$10.35 - $12.49 $153,459 - $185,189
14,827 Added 4.66%
332,695 $3.92 Million
Q1 2024

May 14, 2024

SELL
$11.07 - $16.04 $95,511 - $138,393
-8,628 Reduced 2.64%
317,868 $3.77 Million
Q4 2023

Feb 13, 2024

BUY
$7.58 - $12.25 $388,687 - $628,155
51,278 Added 18.63%
326,496 $4 Million
Q3 2023

Nov 13, 2023

BUY
$8.95 - $11.35 $121,737 - $154,382
13,602 Added 5.2%
275,218 $2.65 Million
Q2 2023

Aug 11, 2023

BUY
$7.73 - $10.57 $197,138 - $269,566
25,503 Added 10.8%
261,616 $2.35 Million
Q1 2023

May 15, 2023

SELL
$6.3 - $8.39 $36,855 - $49,081
-5,850 Reduced 2.42%
236,113 $1.86 Million
Q4 2022

Feb 13, 2023

SELL
$4.2 - $14.24 $11,478 - $38,917
-2,733 Reduced 1.12%
241,963 $1.64 Million
Q3 2022

Nov 14, 2022

BUY
$9.85 - $16.83 $4,708 - $8,044
478 Added 0.2%
244,696 $3.55 Million
Q2 2022

Aug 12, 2022

SELL
$8.16 - $15.1 $28,217 - $52,215
-3,458 Reduced 1.4%
244,218 $2.4 Million
Q1 2022

May 13, 2022

SELL
$11.2 - $16.97 $81,009 - $122,744
-7,233 Reduced 2.84%
247,676 $3.65 Million
Q4 2021

Feb 08, 2022

BUY
$12.36 - $18.28 $261,648 - $386,969
21,169 Added 9.06%
254,909 $3.37 Million
Q3 2021

Nov 15, 2021

SELL
$17.11 - $24.49 $138,471 - $198,197
-8,093 Reduced 3.35%
233,740 $4.08 Million
Q2 2021

Aug 13, 2021

BUY
$23.12 - $29.91 $304,328 - $393,705
13,163 Added 5.76%
241,833 $5.79 Million
Q1 2021

May 12, 2021

SELL
$14.69 - $42.57 $8,432 - $24,435
-574 Reduced 0.25%
228,670 $5.88 Million
Q4 2020

Feb 11, 2021

SELL
$12.88 - $19.47 $124,317 - $187,924
-9,652 Reduced 4.04%
229,244 $4.35 Million
Q3 2020

Nov 16, 2020

SELL
$9.83 - $13.99 $32,409 - $46,125
-3,297 Reduced 1.36%
238,896 $3.01 Million
Q2 2020

Aug 14, 2020

BUY
$6.75 - $12.89 $357,142 - $682,009
52,910 Added 27.95%
242,193 $2.93 Million
Q1 2020

May 14, 2020

BUY
$5.8 - $18.56 $20,381 - $65,219
3,514 Added 1.89%
189,283 $1.45 Million
Q4 2019

Feb 14, 2020

BUY
$10.31 - $17.81 $74,726 - $129,086
7,248 Added 4.06%
185,769 $3.31 Million
Q3 2019

Nov 13, 2019

BUY
$11.6 - $21.67 $1.21 Million - $2.27 Million
104,691 Added 141.8%
178,521 $2.07 Million
Q2 2019

Aug 13, 2019

BUY
$18.44 - $30.89 $607,229 - $1.02 Million
32,930 Added 80.51%
73,830 $1.64 Million
Q1 2019

May 13, 2019

BUY
$16.51 - $31.1 $2,839 - $5,349
172 Added 0.42%
40,900 $1.17 Million
Q4 2018

Feb 12, 2019

BUY
$16.21 - $24.06 $162,651 - $241,418
10,034 Added 32.69%
40,728 $805,000
Q3 2018

Nov 14, 2018

BUY
$8.0 - $22.11 $245,552 - $678,644
30,694 New
30,694 $678,000

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $204M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.